Financials data is unavailable for this security.
View more
Year on year ZIM Laboratories Ltd 's revenues fell -7.80% from 3.99bn to 3.67bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 244.35m to 172.46m, a -29.42% decrease.
| Gross margin | 53.76% |
|---|---|
| Net profit margin | 4.69% |
| Operating margin | 7.25% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, ZIM Laboratories Ltd increased its cash reserves by 49.52%, or 31.80m. Cash Flow from Financing totalled 595.34m or 16.20% of revenues. In addition the company generated 162.78m in cash from operations while cash used for investing totalled 730.13m.
| Cash flow per share | 7.09 |
|---|---|
| Price/Cash flow per share | 15.33 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items dropped -29.42%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| EPS growth(5 years) | -17.83 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -41.11 |
